Chronic Treatment With a Melanocortin-4 Receptor Agonist Causes Weight Loss, Reduces Insulin Resistance, and Improves Cardiovascular Function in Diet-Induced Obese Rhesus Macaques

Targeted disruption of the melanocortin-4 receptor results in obesity in mice

Huszar, D., Lynch, C. A., Fairchild-Huntress, V., Dunmore, J. H., Fang, Q., Berkemeier, L. R., Gu, W., Kesterson, R. A., Boston, B. A., Cone, R. D., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)81865-6 · Cited by 3,030

Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus

Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356

Role of melanocortinergic neurons in feeding and the agouti obesity syndrome

Fan, W., Boston, B. A., Kesterson, R. A., Hruby, V. J., & Cone, R. D. (1997) · Nature · doi:10.1038/385165a0 · Cited by 1,924

Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene

Farooqi, I. S., Keogh, J. M., Yeo, G. S. H., Lank, E. J., Cheetham, T., & O'Rahilly, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022050 · Cited by 1,778

Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans

Krude, H., Biebermann, H., Luck, W., Horn, R., Brabant, G. E., & Grüters, A. (1998) · Nature Genetics · doi:10.1038/509 · Cited by 1,769

A frameshift mutation in MC4R associated with dominantly inherited human obesity

Yeo, G. S. H., Farooqi, I. S., Aminian, S., Halsall, D. J., Stanhope, R. G., & O'Rahilly, S. (1998) · Nature Genetics · doi:10.1038/2404 · Cited by 1,159

A frameshift mutation in human MC4R is associated with a dominant form of obesity

Vaisse, C., Clément, K., Guy-grand, B., & Froguel, P. (1998) · Nature Genetics · doi:10.1038/2407 · Cited by 1,091

Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates

McCurdy, C. E., Bishop, J. M., Williams, S., Grayson, B. E., Smith, M. S., Friedman, J. E., & Grove, K. L. (2009) · Journal of Clinical Investigation · doi:10.1172/jci32661 · Cited by 614

Integration of NPY, AGRP, and Melanocortin Signals in the Hypothalamic Paraventricular Nucleus

Cowley, M. A., Pronchuk, N., Fan, W., Dinulescu, D. M., Colmers, W. F., & Cone, R. D. (1999) · Neuron · doi:10.1016/s0896-6273(00)80829-6 · Cited by 612

Modulation of Blood Pressure by Central Melanocortinergic Pathways

Greenfield, J. R., Miller, J. W., Keogh, J. M., Henning, E., Satterwhite, J. H., Cameron, G. S., Astruc, B., Mayer, J. P., Brage, S., See, T. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803085 · Cited by 477

Anti-obesity drug discovery: advances and challenges

Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021

Animal models of obesity and diabetes mellitus

Kleinert, M., Clemmensen, C., Hofmann, S. M., Moore, M. C., Renner, S., Woods, S. C., Huypens, P., Beckers, J., de Angelis, M. H., Schürmann, A., et al. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.161 · Cited by 893

Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity

Timper, K., & Brüning, J. C. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.026609 · Cited by 851

Melanocortin-4 receptor–regulated energy homeostasis

Krashes, M. J., Lowell, B. B., & Garfield, A. S. (2016) · Nature Neuroscience · doi:10.1038/nn.4202 · Cited by 372

Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?

Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency

Collet, T.-H., Dubern, B., Mokrosinski, J., Connors, H., Keogh, J. M., Mendes de Oliveira, E., Henning, E., Poitou-Bernert, C., Oppert, J.-M., Tounian, P., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.015 · Cited by 302

Gut-Brain Cross-Talk in Metabolic Control

Clemmensen, C., Müller, T. D., Woods, S. C., Berthoud, H., Seeley, R. J., & Tschöp, M. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.025 · Cited by 309

Human gain-of-function MC4R variants show signaling bias and protect against obesity

Lotta, L. A., Mokrosiński, J., Mendes de Oliveira, E., Li, C., Sharp, S. J., Luan, J., Brouwers, B., Ayinampudi, V., Bowker, N., Kerrison, N., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.044 · Cited by 284

Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016

Huvenne, H., Dubern, B., Clément, K., & Poitou, C. (2016) · Obesity Facts · doi:10.1159/000445061 · Cited by 302

The melanocortin pathway and control of appetite-progress and therapeutic implications

Baldini, G., & Phelan, K. D. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0596 · Cited by 300

Pharmacotherapy of obesity: available medications and drugs under investigation.

Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248

The melanocortin pathway and energy homeostasis: From discovery to obesity therapy

Yeo, G. S. H., Chao, D. H. M., Siegert, A., Koerperich, Z. M., Ericson, M. D., Simonds, S. E., Larson, C. M., Luquet, S. H., Clarke, I. J., Sharma, S. D., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101206 · Cited by 254

Neural Control of Energy Balance: Translating Circuits to Therapies

Gautron, L., Elmquist, J. K., & Williams, K. W. (2015) · Cell · doi:10.1016/j.cell.2015.02.023 · Cited by 250

Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon

Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232

Bacterial ClpB heat-shock protein, an antigen-mimetic of the anorexigenic peptide α-MSH, at the origin of eating disorders

Tennoune, N., Chan, P., Breton, J., Legrand, R., Chabane, Y. N., Akkermann, K., Järv, A., Ouelaa, W., Takagi, K., Ghouzali, I., et al. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.98 · Cited by 218

Setmelanotide: First Approval

Markham, A. (2021) · Drugs · doi:10.1007/s40265-021-01470-9 · Cited by 214

POMC neuronal heterogeneity in energy balance and beyond: an integrated view

Quarta, C., Claret, M., Zeltser, L. M., Williams, K. W., Yeo, G. S. H., Tschöp, M. H., Diano, S., Brüning, J. C., & Cota, D. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00345-3 · Cited by 194

Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment

Kühnen, P., Krude, H., & Biebermann, H. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.002 · Cited by 196

Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys

Blevins, J. E., Graham, J. L., Morton, G. J., Bales, K. L., Schwartz, M. W., Baskin, D. G., & Havel, P. J. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00441.2014 · Cited by 191

Obesity: Current and potential pharmacotherapeutics and targets

Narayanaswami, V., & Dwoskin, L. P. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.015 · Cited by 188

The Melanocortin-4 Receptor Is Expressed in Enteroendocrine L Cells and Regulates the Release of Peptide YY and Glucagon-like Peptide 1 In Vivo

Panaro, B. L., Tough, I. R., Engelstoft, M. S., Matthews, R. T., Digby, G. J., Møller, C. L., Svendsen, B., Gribble, F., Reimann, F., Holst, J. J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.004 · Cited by 179

RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals

Chen, K. Y., Muniyappa, R., Abel, B. S., Mullins, K. P., Staker, P., Brychta, R. J., Zhao, X., Ring, M., Psota, T. L., Cone, R. D., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4024 · Cited by 174

Brown, Beige, and White: The New Color Code of Fat and Its Pharmacological Implications

Pfeifer, A., & Hoffmann, L. S. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124346 · Cited by 168

60 YEARS OF POMC: Regulation of feeding and energy homeostasis by α-MSH

Anderson, E. J. P., Çakır, I., Carrington, S. J. S., Cone, R. D., Ghamari‐Langroudi, M., Gillyard, T. R., Gimenez, L. E., & Litt, M. J. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0014 · Cited by 158

Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss

Christoffersen, B. Ø., Sanchez‐Delgado, G., John, L. M., Ryan, D. H., Raun, K., & Ravussin, E. (2022) · Obesity · doi:10.1002/oby.23374 · Cited by 142

Translational and therapeutic potential of oxytocin as an anti-obesity strategy: Insights from rodents, nonhuman primates and humans

Blevins, J. E., & Baskin, D. G. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.05.023 · Cited by 135

Latest approaches for the treatment of obesity

Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1044966 · Cited by 132

Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy

Angelidi, A. M., Belanger, M. J., Kokkinos, A. D., Koliaki, C. C., & Mantzoros, C. S. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 141

Neural melanocortin receptors in obesity and related metabolic disorders

Girardet, C., & Butler, A. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.004 · Cited by 128

The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options

Fani, L., Bak, S., Delhanty, P., van Rossum, E. F. C., & van den Akker, E. L. T. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.80 · Cited by 121

Chronic CNS oxytocin signaling preferentially induces fat loss in high-fat diet-fed rats by enhancing satiety responses and increasing lipid utilization

Blevins, J. E., Thompson, B. W., Anekonda, V. T., Ho, J. M., Graham, J. L., Roberts, Z. S., Hwang, B. H., Ogimoto, K., Wolden‐Hanson, T., Nelson, J. T., et al. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00220.2015 · Cited by 109

The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis

Lawson, E. A., Olszewski, P. K., Weller, A., & Blevins, J. E. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12805 · Cited by 100

Pediatric obesity: Current concepts

Greydanus, D. E., Agana, M. G., Kamboj, M. K., Shebrain, S., Soares, N. S., Eke, R., & Patel, D. R. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2017.12.001 · Cited by 104

Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications

Gong, M., Wen, S., Nguyen, T., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s232377 · Cited by 95

Current and emerging therapies for managing hyperphagia and obesity in Prader‐Willi syndrome: A narrative review

Tan, Q., Orsso, C. E., Deehan, E. C., Triador, L., Field, C. J., Tun, H. M., Han, J. C., Müller, T. D., & Haqq, A. M. (2019) · Obesity Reviews · doi:10.1111/obr.12992 · Cited by 99

Brain Signaling Systems in the Type 2 Diabetes and Metabolic Syndrome: Promising Target to Treat and Prevent These Diseases

Shpakov, A. O., Derkach, K. V., & Berstein, L. M. (2015) · Future Science OA · doi:10.4155/fso.15.23 · Cited by 93

Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment

Ayers, K. L., Glicksberg, B. S., Garfield, A. S., Longerich, S., White, J., Yang, P., Du, L., Chittenden, T. W., Gulcher, J. R., Roy, S., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00258 · Cited by 96

Synaptic changes induced by melanocortin signalling

Caruso, V., Lagerström, M. C., Olszewski, P. K., Fredriksson, R., & Schiöth, H. B. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3657 · Cited by 90

Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice

Clemmensen, C., Finan, B., Fischer, K., Tom, R. Z., Legutko, B., Sehrer, L., Heine, D., Grassl, N., Meyer, C. W., Henderson, B., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404508 · Cited by 89

Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016

Ericson, M. D., Lensing, C. J., Fleming, K. A., Schlasner, K. N., Doering, S. R., & Haskell‐Luevano, C. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.03.020 · Cited by 91

Biased signaling at neural melanocortin receptors in regulation of energy homeostasis

Yang, L.-K., & Tao, Y. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.04.010 · Cited by 84

2020 FDA TIDES (Peptides and Oligonucleotides) Harvest

Musaimi, O. A., Shaer, D. A., Alberício, F., & de la Torre, B. G. (2021) · Pharmaceuticals · doi:10.3390/ph14020145 · Cited by 89

Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists

Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81

Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice

Gan, L., Meng, Z., Xiong, R.-B., Guo, J., Xiao-cui, L., Zheng, Z.-W., Deng, Y., Luo, B., Zou, F., & Li, H. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.11 · Cited by 78

Use and importance of nonhuman Primates in metabolic disease research: current state of the field

Havel, P. J., Kievit, P., Comuzzie, A. G., & Bremer, A. A. (2017) · ILAR Journal · doi:10.1093/ilar/ilx031 · Cited by 75

The Role of Obesity and Diabetes in Dementia

Selman, A., Burns, S., Reddy, A. P., Culberson, J. W., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169267 · Cited by 72

Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation

Sharma, S., Garfield, A., Shah, B. P., Kleyn, P., Ichetovkin, I., Moeller, I., Mowrey, W. R., & van der Ploeg, L. (2019) · Molecules · doi:10.3390/molecules24101892 · Cited by 53

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

Ryan, D. H. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21033 · Cited by 67

A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates

Rangwala, S. M., D’Aquino, K. E., Zhang, Y.-M., Bader, L., Edwards, W., Zheng, S., Eckardt, A. J., Lacombe, A., Pick, R. R., Moreno, V., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.017 · Cited by 67

FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys

Andersen, B., Straarup, E. M., Heppner, K. M., Takahashi, D. L., Raffaele, V., Dissen, G. A., Lewandowski, K., Bödvarsdottir, T. B., Raun, K., Grove, K. L., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0080-7 · Cited by 66

Whole-brain activation signatures of weight-lowering drugs

Hansen, H. H., Perens, J., Roostalu, U., Skytte, J. L., Salinas, C. G., Barkholt, P., Thorbek, D. D., Rigbolt, K. T. G., Vrang, N., Jelsing, J., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101171 · Cited by 65

The role of the microbiota in sedentary lifestyle disorders and ageing: lessons from the animal kingdom

O’Toole, P. W., & Shiels, P. G. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13021 · Cited by 63

Pathophysiology of melanocortin receptors and their accessory proteins

Novoselova, T. V., Chan, L. F., & Clark, A. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.02.002 · Cited by 59

Uroguanylin Action in the Brain Reduces Weight Gain in Obese Mice via Different Efferent Autonomic Pathways

Folgueira, C., Beiroa, D., Callon, A., Al–Massadi, O., Barja-Fernández, S., Senra, A., Fernø, J., López, M., Diéguez, C., Casanueva, F. F., et al. (2015) · Diabetes · doi:10.2337/db15-0889 · Cited by 56

Leveraging Melanocortin Pathways to Treat Glomerular Diseases

Gong, R. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2013.09.004 · Cited by 56

Medications for the treatment of obesity in adolescents

Woodard, K. T., Louque, L., & Hsia, D. S. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820918789 · Cited by 56

The nonhuman primate as a model for type 2 diabetes

Pound, L. D., Kievit, P., & Grove, K. L. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000043 · Cited by 54

Rare genetic forms of obesity: From gene to therapy

Clément, K., Mosbah, H., & Poitou, C. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.113134 · Cited by 57

Maternal and postnatal high-fat diet consumption programs energy balance and hypothalamic melanocortin signaling in nonhuman primate offspring

Sullivan, E. L., Rivera, H. M., True, C. A., Franco, J. G., Baquero, K. C., Dean, T. A., Valleau, J. C., Takahashi, D. L., Frazee, T., Hanna, G. S., et al. (2017) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00309.2016 · Cited by 53

Hypertension in obesity: is leptin the culprit?

Simonds, S. E., & Cowley, M. A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.01.004 · Cited by 50

Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development

Mittermayer, F., Caveney, E. J., OLIVEIRA, C. D. F., Gourgiotis, L., Puri, M., Tai, L.-J., & Turner, J. R. (2015) · Current Diabetes Reviews · doi:10.2174/1573399810666141224121927 · Cited by 48

Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity

Trapp, C. M., & Censani, M. (2023) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000798 · Cited by 41

Astrocytes: new targets of melanocortin 4 receptor actions

Caruso, C. M., Carniglia, L., Durand, D., Scimonelli, T. N., & Lasaga, M. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0064 · Cited by 42

Neurotransmitters in Type 2 Diabetes and the Control of Systemic and Central Energy Balance

Al-Sayyar, A., Hammad, M. M., Williams, M. R., Al‐Onaizi, M., Abubaker, J. A., & Alzaïd, F. (2023) · Metabolites · doi:10.3390/metabo13030384 · Cited by 45

Role of the brain melanocortins in blood pressure regulation

do Carmo, J. M., da Silva, A. A., Wang, Z., Fang, T., Aberdein, N., Perez de Lara, C. E., & Hall, J. E. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.03.003 · Cited by 38

POMC Neurons Dysfunction in Diet-induced Metabolic Disease: Hallmark or Mechanism of Disease?

Quarta, C., Fioramonti, X., & Cota, D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.031 · Cited by 41

A cellular and molecular basis of leptin resistance

Tan, B., Hedbacker, K., Kelly, L., Zhang, Z., Moura‐Assis, A., Luo, J., Rabinowitz, J. D., & Friedman, J. M. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.001 · Cited by 45

Control of metabolic and cardiovascular function by the leptin–brain melanocortin pathway

do Carmo, J. M., da Silva, A. A., Dubinion, J., Sessums, P. O., Ebaady, S. H., Wang, Z., & Hall, J. E. (2013) · IUBMB Life · doi:10.1002/iub.1187 · Cited by 36

Signal Transduction and Pathogenic Modifications at the Melanocortin-4 Receptor: A Structural Perspective

Heyder, N., Kleinau, G., Szczepek, M., Kwiatkowski, D., Speck, D., Soletto, L., Cerdá‐Reverter, J. M., Krude, H., Kühnen, P., Biebermann, H., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00515 · Cited by 37

Magel2‐null mice are hyper‐responsive to setmelanotide, a melanocortin 4 receptor agonist

Bischof, J. M., der Ploeg, L. H. T. V., Colmers, W. F., & Wevrick, R. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13540 · Cited by 36

The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain

Li, L., Yoo, E.-S., Li, X., Wyler, S. C., Chen, X., Wan, R., Arnold, A. G., Birnbaum, S. G., Jia, L., Sohn, J., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202484 · Cited by 34

Biphasic Effect of Melanocortin Agonists on Metabolic Rate and Body Temperature

Lute, B., Jou, W., Lateef, D. M., Goldgof, M., Xiao, C., Piñol, R. A., Kravitz, A. V., Miller, N., Huang, Y. G., Clemence, G., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.021 · Cited by 35

Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus

Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34

A Life without Hunger: The Ups (and Downs) to Modulating Melanocortin-3 Receptor Signaling

Butler, A. A., Clemence, G., Mavrikaki, M., Trevaskis, J. L., Macarthur, H., Marks, D. L., & Farr, S. A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00128 · Cited by 36

Control of respiratory and cardiovascular functions by leptin

Bassi, M., Furuya, W. I., Zoccal, D. B., Menani, J. V., Colombari, E., Hall, J. E., da Silva, A. A., do Carmo, J. M., & Colombari, D. S. A. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.01.019 · Cited by 34

Drugs for Treating Obesity

Ryan, D. H. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_560 · Cited by 37

Late onset obesity in mice with targeted deletion of potassium inward rectifier Kir7.1 from cells expressing the melanocortin‐4 receptor

Anderson, E. J. P., Ghamari‐Langroudi, M., Çakır, I., Litt, M. J., Chen, V., Reggiardo, R. E., Millhauser, G. L., & Cone, R. D. (2018) · Journal of Neuroendocrinology · doi:10.1111/jne.12670 · Cited by 30

A Brain-Melanocortin-Vagus Axis Mediates Adipose Tissue Expansion Independently of Energy Intake

Holland, J., Sorrell, J. E., Yates, E., Smith, K., Arbabi, S., Arnold, M., Rivir, M., Morano, R. L., Chen, J., Zhang, X., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.089 · Cited by 28

Recent Advances in Hypertension

Oliveira, V., Kwitek, A. E., Sigmund, C. D., Morselli, L. L., & Grobe, J. L. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.14513 · Cited by 30

Oxytocin as an Anti-obesity Treatment

Niu, J., Tong, J., & Blevins, J. E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.743546 · Cited by 30

Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment

Teoh, S. L., & Das, S. (2016) · Tumor Biology · doi:10.1007/s13277-016-5357-7 · Cited by 29

Structural Complexity and Plasticity of Signaling Regulation at the Melanocortin-4 Receptor

Kleinau, G., Heyder, N., Tao, Y., & Scheerer, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165728 · Cited by 30

Melanocortin Pathways: Suppressed and Stimulated Melanocortin-4 Receptor (MC4R)

Hainer, V., Hainerová, I. A., Kunešová, M., Braunerová, R. T., Zamrazilová, H., & Bendlová, B. (2020) · Physiological Research · doi:10.33549/physiolres.934512 · Cited by 28

The Long Way of Oxytocin from the Uterus to the Heart in 70 Years from Its Discovery

Camerino, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032556 · Cited by 33

Temporal cAMP Signaling Selectivity by Natural and Synthetic MC4R Agonists

Molden, B., Cooney, K. A., West, K. L., der Ploeg, L. H. T. V., & Baldini, G. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1071 · Cited by 28

Pharmacological Activation of the Melanocortin System Limits Plaque Inflammation and Ameliorates Vascular Dysfunction in Atherosclerotic Mice

Rinne, P., Silvola, J. M. U., Hellberg, S., Ståhle, M. R., Liljenbäck, H., Salomäki, H., Koskinen, E., Nuutinen, S., Saukko, P. J., Knuuti, J. M., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302963 · Cited by 26

Bacterial Protein Mimetic of Peptide Hormone as a New Class of Protein- based Drugs

Fetissov, S. O., Legrand, R., & Lucas, N. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666171005110620 · Cited by 27

Novel α-MSH analog causes weight loss in obese rats and minipigs and improves insulin sensitivity

Fosgerau, K., Raun, K., Nilsson, C., Dahl, K., & Wulff, B. S. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0284 · Cited by 25

Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies

Jackson, V. M., Price, D. A., & Carpino, P. A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918952 · Cited by 24

Molecular Therapy of Melanocortin-4-Receptor Obesity by an Autoregulatory BDNF Vector

Siu, J. J., Queen, N. J., Liu, X., Huang, W., McMurphy, T. B., & Cao, L. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.09.005 · Cited by 23

Current and Emerging Treatment Options in Diabetes Care

Clemmensen, C., Müller, T. D., Finan, B., Tschöp, M. H., & DiMarchi, R. D. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_7 · Cited by 22

The central melanocortin system as a treatment target for obesity and diabetes: A brief overview

Goit, R. K., Taylor, A. W., & Lo, A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174956 · Cited by 22

Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin

Yuan, X., & Tao, Y. (2022) · Biomolecules · doi:10.3390/biom12101407 · Cited by 23

GEOFFREY HARRIS PRIZE LECTURE 2018: Novel pathways regulating neuroendocrine function, energy homeostasis and metabolism in humans

Papathanasiou, A. E., Nolen-Doerr, E., Farr, O. M., & Mantzoros, C. S. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0847 · Cited by 20

The renin–angiotensin system in the arcuate nucleus controls resting metabolic rate

Deng, G., & Grobe, J. L. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000477 · Cited by 20

Setmelanotide: what does it mean for clinical care of patients with obesity?

Ryan, D. H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30366-1 · Cited by 20

The unique structural characteristics of the Kir 7.1 inward rectifier potassium channel: a novel player in energy homeostasis control

Hernández, C. C., Gimenez, L. E., Dahir, N. S., Peisley, A., & Cone, R. D. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00335.2022 · Cited by 18

Effects of a novel MC4R agonist on maintenance of reduced body weight in diet‐induced obese mice

Skowronski, A. A., Morabito, M. V., Mueller, B. R., Lee, S., Hjorth, S., Lehmann, A., Watanabe, K., Zeltser, L. M., Ravussin, Y., ROSENBAUM, M. S., et al. (2013) · Obesity · doi:10.1002/oby.20678 · Cited by 18

Estradiol Replacement Timing and Obesogenic Diet Effects on Body Composition and Metabolism in Postmenopausal Macaques

Purnell, J. Q., Urbanski, H. F., Kievit, P., Roberts, C. T., & Bethea, C. L. (2019) · Endocrinology · doi:10.1210/en.2018-00884 · Cited by 18

Recent progress in the pharmacotherapy for obesity

Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17

Novel melanocortin 4 receptor agonist causes weight loss in obese rhesus macaques

Greenhill, C. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.202 · Cited by 2

Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice

Kumar, K. G., Sutton, G. M., Dong, J. Z., Roubert, P., Plas, P., Halem, H. A., Culler, M. D., Yang, H., Dixit, V. D., & Butler, A. A. (2009) · Peptides · doi:10.1016/j.peptides.2009.07.012 · Cited by 98

The effect of melanocortin-4 receptor agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis

Sun, Y., Abed, M., & Sohouli, M. H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02071-2 · Cited by 1

Melanocortin-4 Receptor Modulators for the Treatment of Obesity: a Patent Analysis (2008–2014)

Lee, E. C. Y., & Carpino, P. A. (2015) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.15.1 · Cited by 10

Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment

Kühnen, P., Krude, H., & Biebermann, H. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.002 · Cited by 196